TELA Bio (TELA) Preferred Stock Liabilities (2018 - 2019)
TELA Bio's (TELA) quarterly Preferred Stock Liabilities came in at $1.6 million in Q3 2019, down 94.97% year-on-year from $32.7 million in Q3 2018, and down 95.17% quarter-over-quarter from $34.0 million in Q2 2019.
TELA Bio (TELA) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
TELA Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $1.6 million for Q3 2019.
- On a quarterly basis, Preferred Stock Liabilities fell 94.97% year-over-year to $1.6 million in Q3 2019; TTM through Sep 2019 was $1.6 million, a 94.97% decrease from a year earlier, with the FY2018 full-year figure at $1.6 million, down 97.96% from the prior year.
- Preferred Stock Liabilities eased to $1.6 million in Q3 2019 per TELA's latest filing, from $34.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $34.0 million in Q2 2019 and bottomed at $1.6 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | TELA Bio | 40.65 Mn | 1.11 Mn | 12.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 1.64 Mn |
| Jun 30, 2019 | 34.01 Mn |
| Dec 31, 2018 | 1.64 Mn |
| Sep 30, 2018 | 32.66 Mn |